Recent advances in CAR T and CAR NK cell therapy for AML - PubMed
4 hours ago
- #CAR T cell therapy
- #CAR NK cell therapy
- #Acute myeloid leukemia
- CAR T cell therapy has shown significant success in treating B-cell lymphomas, B-cell leukemias, and multiple myeloma, but is urgently needed for acute myeloid leukemia (AML).
- A major challenge in CAR T therapy for AML is identifying AML-specific antigens, as candidates like CD33, CD123, and CLL-1 are also expressed on normal hematopoietic cells, risking bone marrow aplasia and on-target/off-tumor toxicity.
- CAR NK cell therapy is a promising alternative for AML due to its lower toxicity, off-the-shelf availability, reduced risk of graft-versus-host disease (GVHD), and potentially milder cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
- The review covers the current status of CAR T and CAR NK cell development for AML and introduces a new therapy targeting mismatched HLA-DRB1 for AML patients who relapsed after allogeneic hematopoietic stem cell transplant.